Resmed delivered a strong quarterly result with record revenue and income for the period

James Marlay

Livewire Markets

Resmed delivered a strong quarterly result with record revenue and income for the period. Revenue was $397.8million, a 4% increase over the quarter ended March 31, 2013. Net income was $90.0 million an increase of 6% compared to the quarter ended March 31, 2013. In our most recent Buy Hold Sell episode Roger Montgomery, CIO of Montgomery Investment Management, and Don Williams, CIO of Platypus Asset Management, both share their views on Resmed (amongst other healthcare stocks). Both Fund managers rate Resmed as a Buy, citing that the business is coming out of a tough period and growth in the treatment of sleep apnea has plenty of room to go. Earlier this week Livewire contributor Michael Gable also suggested Resmed is now in Buy territory, currently trading at $5.10 Gable sees a long term target of $6. Video here: & Michael's wire here: (VIEW LINK)


James Marlay
Co Founder
Livewire Markets

Livewire is Australia’s #1 website for expert investment analysis. We work with leading investment professionals to deliver curated content that helps investors make confident and informed decisions. Safe investing and thanks for reading Livewire.

Expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.